In a Phase 3 trial published at NEJM.org, Dizal Pharmaceuticals’ sunvozertinib outperformed chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. The randomized study reported median progression-free survival of 10.3 months with sunvozertinib versus 7.5 months with carboplatin–pemetrexed, alongside higher objective response rates, though grade 3-plus adverse events were more frequent on sunvozertinib than on chemotherapy.